eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
Share:
Send email
Share:
Original paper

The relationship between mutation carriage of BRCA1/2 and clinicopathological characteristics in women with breast cancer: experience from a diagnostic centre in Turkey

Neslihan Duzkale
1
,
Onur Can Guler
2
,
Suat Kutun
2
,
Canan Emiroglu
3
,
Serdar Saridemir
2
,
Aysun Gokce
4
,
Olcay Kandemir
4
,
Tugba Taskın Turkmenoglu
4
,
Serap Yorubulut
5
,
Bahadır Kulah
6

  1. Department of Medical Genetic, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey
  2. Department of Surgical Oncology, Ankara Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
  3. Department of Family Medicine, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey
  4. Department of Pathology, Ankara Etlik City Hospital, Ankara, Turkey
  5. Department of Statistics, Kırıkkale University, Faculty of Science and Letters, Ankara, Turkey
  6. Department of General Surgery, Ankara A Life Hospital, Ankara, Turkey
Pol J Pathol 2024; 75 (3):
DOI: https://doi.org/10.5114/pjp.2024.142750
Online publish date: 2024/09/05
Article file
- The relationship between (1).pdf  [0.33 MB]
Get citation
 
PlumX metrics:
 
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-249.
2. Ruiz de Sabando A, García-Amigot F, Moreno S, et al. Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain) [published correction appears in BMC Cancer 2019 Dec 17; 19: 1227]. BMC Cancer 2019; 19: 1145.
3. Rosen EM, Fan S, Pestell RG, et al. BRCA1 gene in breast cancer. J Cell Physiol 2003; 196: 19-41.
4. Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. In: Adam MP, Mirzaa GM, Pagon RA, et al. (eds.). GeneReviews®, University of Washington, Seattle (WA)1998.
5. Akcay IM, Celik E, Agaoglu NB, et al. Germline pathogenic variant spectrum in 25 cancer susceptibility genes in Turkish breast and colorectal cancer patients and elderly controls. Int J Cancer 2021; 148: 285-295.
6. Beck AC, Yuan H, Liao J, et al. Rate of BRCA mutation in patients tested under NCCN genetic testing criteria. Am J Surg 2020; 219: 145-149.
7. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
8. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405-424.
9. Balci A, Huusko P, Pääkkönen K, et al. Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: a novel mutation BRCA2 3414del4 found in male breast cancer. Eur J Cancer 1999; 35: 707-710.
10. Ozdag H, Tez M, Sayek I, et al. Germ line BRCA1 and BRCA2 gene mutations in Turkish breast cancer patients. Eur J Cancer 2000; 36: 2076-2082.
11. Yazici H, Bitisik O, Akisik E, et al. BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients. Br J Cancer 2000; 83: 737-742.
12. Manguoglu AE, Lüleci G, Ozçelik T, et al. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients. Hum Mutat 2003; 21: 444-445.
13. Güran S, Ozet A, Dede M, Gille JJ, Yenen MC. Hereditary breast cancer syndromes in a Turkish population. Results of molecular germline analysis. Cancer Genet Cytogenet 2005; 160: 164-168.
14. Egeli U, Cecener G, Tunca B, Tasdelen I. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives. Cancer Invest 2006; 24: 484-491.
15. Manguoğlu E, Güran S, Yamaç D, et al. Germline mutations of BRCA1 and BRCA2 genes in Turkish breast, ovarian, and prostate cancer patients. Cancer Genet Cytogenet 2010; 203: 230-237.
16. Manguoğlu E, Güran S, Yamaç D, et al. Genomic large rearrangement screening of BRCA1 and BRCA2 genes in high-risk Turkish breast/ovarian cancer patients by using multiplex ligation-dependent probe amplification assay. Cancer Invest 2011; 29: 73-77.
17. Aydin F, Akagun T, Yildiz B, Fidan E, Ozdemir F, Kavgaci H. Clinicopathologic characteristics and BRCA-1/BRCA-2 mutations of Turkish patients with breast cancer. Bratisl Lek Listy 2011; 112: 521-523.
18. Cecener G, Egeli U, Tunca B, et al. BRCA1/2 germline mutations and their clinical importance in Turkish breast cancer patients. Cancer Invest 2014; 32: 375-387.
19. Yazıcı H, Kılıç S, Akdeniz D, et al. Frequency of rearrangements versus small ındels mutations in BRCA1 and BRCA2 genes in Turkish patients with high risk breast and ovarian cancer. Eur J Breast Health 2018; 14: 93-99.
20. Bisgin A, Boga I, Yalav O, Sonmezler O, Tug Bozdogan S. BRCA mutation characteristics in a series of index cases of breast cancer selected independent of family history. Breast J 2019; 25: 1029-1033.
21. Geredeli C, Yasar N, Sakin A. Germline mutations in BRCA1 and BRCA2 in breast cancer patients with high genetic risk in Turkish population. Int J Breast Cancer 2019; 2019: 9645147.
22. Bahsi T, Erdem H. Spectrum of BRCA1/BRCA2 variants in 1419 Turkish breast and ovarian cancer patients: a single center study. Türk Biyokimya Dergisi 2020; 45: 83-90.
23. Demir S, Tozkir H, Gurkan H, et al. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey. J BUON 2020; 25: 1337-1347.
24. Peker Eyüboğlu İ, Yenmiş G, Bingöl EN, et al. Next-generation sequencing identifies BRCA1 and/or BRCA2 mutations in women at high hereditary risk for breast cancer with shorter telomere length. OMICS 2020; 24: 5-15.
25. Atcı MM, Geredeli Ç, Ay S, et al. Clinical and pathological characteristics of patients with high-risk breast cancer based on BRCA mutation profiles: a retrospective study. Eur J Breast Health 2021; 17: 123-127.
26. Ödemiş DA, Celik B, Kilic Erciyas S, et al. Evaluation of BRCA1/2 gene mutations in patients with high-risk breast and/or ovarian cancer in Turkey. Turk J Biochem 2022; 47: 588-594.
27. Gun-Bilgic D, Aydin-Gumus A, Bilgic A, Cam FS. Mutations of BRCA1/2 genes in the west of Turkey and genotype-phenotype correlations. Clin Lab 2022; 68: 10.7754/Clin.Lab.2021.210425.
28. Bora E, Caglayan AO, Koc A, et al. Evaluation of hereditary/familial breast cancer patients with multigene targeted next generation sequencing panel and MLPA analysis in Turkey. Cancer Genet 2022; 262-263: 118-133.
29. Sunar V, Korkmaz V, Topcu V, et al. Frequency of germline BRCA1/2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer. Asia Pac J Clin Oncol 2022; 18: 84-92.
30. Boga I, Ozemri Sag S, Duman N, et al. A multicenter study of genotype variation/demographic patterns in 2475 individuals including 1444 cases with breast cancer in Turkey. Eur J Breast Health 2023; 19: 235-252. 31.
31. Levy-Lahad E, Catane R, Eisenberg S, et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997; 60: 1059-1067.
32. Rebbeck TR, Friebel TM, Friedman E, et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 2018; 39: 593-620.
33. Ferla R, Calò V, Cascio S, et al. Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 2007; 18: vi93-vi98.
34. Johannesdottir G, Gudmundsson J, Bergthorsson JT, et al. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res 1996; 56: 3663-3665.
35. Górski B, Jakubowska A, Huzarski T, et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 2004; 110: 683-686.
36. Krajc M, Teugels E, Zgajnar J, et al. Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families. BMC Med Genet 2008; 9: 83.
37. Alvarez C, Tapia T, Perez-Moreno E, et al. BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile. Oncotarget 2017; 8: 74233-74243.
38. Metcalfe K, Gershman S, Lynch HT, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2011; 104: 1384-1392.
39. Cinkaya A, Akin M, Sengul A. Evaluation of treatment outcomes of triple-negative breast cancer. J Cancer Res Ther 2016; 12: 150-154.
40. Liu L, Hao X, Song Z, et al. Correlation between family history and characteristics of breast cancer. Sci Rep 2021; 11: 6360.
41. Vargas AC, Reis-Filho JS, Lakhani SR. Phenotype-genotype correlation in familial breast cancer. J Mammary Gland Biol Neoplasia 2011; 16: 27-40.
42. Mavaddat N, Barrowdale D, Andrulis IL, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012; 21: 134-147.
43. Palacios J, Honrado E, Osorio A, et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 2003; 9: 3606-3614.
44. Lakhani SR, Gusterson BA, Jacquemier J, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000; 6: 782-789.
45. Eerola H, Heikkilä P, Tamminen A, et al. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 2005; 7: R93-R100.
46. Kuchenbaecker KB, Neuhausen SL, Robson M, et al. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2014; 16: 3416.
47. McLaughlin JR, Rosen B, Moody J, et al. Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst 2013; 105: 141-148.
48. Grindedal EM, Heramb C, Karsrud I, et al. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers. BMC Cancer 2017; 17: 438.
49. Davaadelger B, Choi MR, Singhal H, et al. BRCA1 mutation influences progesterone response in human benign mammary organoids. Breast Cancer Res 2019; 21: 124.
50. Stevens KN, Vachon CM, Couch FJ. Genetic susceptibility to triple-negative breast cancer. Cancer Res 2013; 73: 2025-2030.
51. Lippi G, Mattiuzzi C, Montagnana M. BRCA population screening for predicting breast cancer: for or against? Ann Transl Med 2017; 5: 275.
Copyright: © 2024 Polish Association of Pathologists and the Polish Branch of the International Academy of Pathology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.